← Back to overview

BMY Bristol-Myers Squibb Company

Pharmaceuticals · $62.09 +0.94%
EN PL
Price Alert:

Compare

Shows % change over the period so different-priced stocks can be compared fairly.

Technical Indicators

RSI (14)
40.3
Relative Strength Index (RSI): measures how fast and how much the price has moved recently, on a 0-100 scale. Above 70 is often called "overbought" (may be due for a pause or pullback); below 30 is "oversold" (may be due for a bounce). It is not a guarantee either way.
SMA 20 / 50 / 200
62.17 / 62.18 / —
Moving Averages (SMA): the average closing price over the last N days, smoothing out day-to-day noise. When price trades above its moving averages, and shorter averages are above longer ones, it is generally read as a healthier trend.
MACD / Signal
0.00 / 0.01
MACD: compares two moving averages (12-day and 26-day) to gauge momentum. When the MACD line crosses above its signal line, momentum is turning up; crossing below suggests momentum turning down.

Fundamentals

P/E
17.4
Price-to-Earnings ratio: how many dollars investors pay for $1 of the company's annual profit. Higher usually means the market expects faster growth (or the stock is expensive); lower can mean it's cheap — or that growth is expected to slow.
Market Cap
126.79B
Market Capitalization: the total value of all the company's shares — share price × number of shares. A rough measure of company size.
Div Yield
4.06%
Dividend Yield: the annual cash dividend paid to shareholders, as a percentage of the current share price.
52-Week Range
42.52 – 62.89
52-Week Range: the lowest and highest price the stock has traded at over the last year. Where the price sits in this range hints at recent strength or weakness.

Trend Analysis

Bristol-Myers Squibb Company is trading at $62.09, +0.94% versus the previous close. The price is near its 52-week high — the top of its recent trading range.
RSI is in a neutral range — no strong overbought/oversold signal.
MACD is below its signal line — momentum currently leans negative.
Combine this reading with the fundamentals below before forming a view — no single indicator is a guarantee of what happens next.

Latest News

Why Agilent Technologies (A) Is Up 5.4% After New FDA Nod For OPDIVO Cancer Test
Simply Wall St. · 2026-07-25 15:12
Is Bristol Myers Squibb's Dividend Too Good to Be True? Here's My Honest Answer
Motley Fool · 2026-07-24 20:50
3 Healthcare Stocks We Keep Off Our Radar
StockStory · 2026-07-24 16:33
Will Moderna (MRNA) Report Negative Earnings Next Week? What You Should Know
Zacks · 2026-07-24 14:00
Bristol Myers Squibb (BMY) Rises As Market Takes a Dip: Key Facts
Zacks · 2026-07-23 21:45
FDA Accepts RVMD's Filing for Daraxonrasib in Pancreatic Cancer
Zacks · 2026-07-23 17:10
Bristol Myers Squibb (BMY) Reports Next Week: Wall Street Expects Earnings Growth
Zacks · 2026-07-23 14:00
Global Procurement Awards 2026 Shortlist Announced
GlobeNewswire · 2026-07-22 17:14
Educational information only. Nothing here is investment advice — always do your own research and consider talking to a licensed financial advisor before buying or selling.
Data: Yahoo Finance, refreshed periodically and cached locally.